Loading
The Swiss trial group's randomised test of adding radiotherapy before lung cancer surgery: it added side effects and no benefit, so chemotherapy and one local treatment are enough.
The report of SAKK 16/00, led from Kantonsspital Winterthur with investigators at CHUV Lausanne, University Hospital Zurich and other centres. Patients with resectable stage IIIA/N2 non-small-cell lung cancer received three cycles of cisplatin and docetaxel and were randomised to 44 Gy of radiotherapy before surgery or to surgery directly. Event-free survival did not differ, and 91 per cent of patients completed the three chemotherapy cycles.
For resectable stage IIIA/N2 disease, induction chemotherapy followed by a single definitive local treatment, surgery or radiotherapy, is adequate; stacking radiotherapy before surgery adds toxicity without improving event-free survival.
Shares Rolf A. Stahel, Swiss Cancer Institute (formerly SAKK), Non-small-cell lung cancer.
Shares Swiss Cancer Institute (formerly SAKK), Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne.
Shares Swiss Cancer Institute (formerly SAKK), University Hospital Zurich / Comprehensive Cancer Center Zurich, Non-small-cell lung cancer.
Shares Roger Stupp, University Hospital Zurich / Comprehensive Cancer Center Zurich, Non-small-cell lung cancer.
Shares Swiss Cancer Institute (formerly SAKK), University Hospital Zurich / Comprehensive Cancer Center Zurich, Non-small-cell lung cancer.
Shares Roger Stupp, University Hospital Zurich / Comprehensive Cancer Center Zurich, Non-small-cell lung cancer.
Shares Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne, Non-small-cell lung cancer.
Shares Roger Stupp, Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne, University Hospital Zurich / Comprehensive Cancer Center Zurich.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/